Referências

1. Diário Oficial da União de 23/02/2022, RE 560. Disponível em: https://www.gov.br/anvisa /pt-br/assuntos/noticiasanvisa/2022/anvisa-aprova-produto-de-terapiaavancada-para-tratamento-de-cancer. Acessado em Janeiro de 2025. 2. Bula de Profissional da Saúde de Kymriah. Versão VPS4. Aprovado pela ANVISA em 11/06/2024. 3. Maude SL et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378:439-48. 4. Rives S et al, Tisagenlecleucel In Pediatric And Young Adult Patients (Pts) With Relapsed/refractory (Rr) B-cell Acute Lymphoblastic Leukemia (B-all): Final Analyses From The Eliana Study Rives S. Hemasphere, 2022, Vol 6, 13-14. 5. John S et al. Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood (2021) 138 (Supplement 1): 428. 6. Schuster SJ et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021; 22: 1403–15. 7. Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–332. 8. Dreyling M et al. Correlative E cacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial. Blood 2022; 140 (Supplement 1): 1459–1468. 9. Schuster S et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B Cell Lymphoma N Engl J Med 2019; 380:45-56. 10. Schuster S et al. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up. Blood (2023) 142 (Supplement 1):601. Nov 2023. 11. Jaeger U et al. Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large. BCell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial. Blood 2020;138 (Supplement 1): 48–49.